Oral antiviral therapy for COVID-19? update to our management guidelines - Jan 26, 2022

Oral antiviral therapy (nirmatrelvir/ritonavir or Paxlovid) is now available in Quebec for selected patients who are at high risk of progression to severe disease AND identified early (<5days) after onset of symptoms.. Beware drug-drug interactions and limited supply - our latest guidelines offer an approach for outpatient management of COVID-19 for vulnerable high-risk patients. Enjoy!

49 views0 comments

Recent Posts

See All

The ASP group is happy to announce the update to the MUHC UTI guidelines! It includes updated MUHC urine culture antibiogram, most frequent uropathogens at our institution, new recommendations for emp

The ASP Committee is happy to upload the following guidelines to the MUHC ASP website: -COVID guidelines V11 and Outpatient COVID management decision tree. -Febrile Neutropenia (update) -Antifungal p

Do you wonder how to treat an aspiration pneumonia? What antibiotic to give in case of an open fracture? Should you give Vancomycin for the treatment of healthcare acquired meningitis? The ASP committ